{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T08:31:13Z","timestamp":1701333073212},"reference-count":50,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Zentralbl Chir"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die gastro\u00f6sophageale Refluxkrankheit (GERD) ist h\u00e4ufig. Protonenpumpeninhibitoren (PPI) gelten als Mittel der ersten Wahl f\u00fcr alle klinischen Manifestationen. Sie wirken allerdings bei mindestens 30% der Patienten unzureichend, zudem werden sie gelegentlich auch nicht vertragen. Einige Patienten w\u00fcnschen sich auch eine therapeutische Alternative. Alginate bewirken eine mechanische Refluxhemmung durch Bildung einer gelartigen Schicht in der sog. Acid Pocket, einem S\u00e4urereservoir, das unmittelbar nach der Nahrungsaufnahme auf dem Speisebrei im Magenkorpus entsteht. Sie kommen zur Symptombehandlung einer unkomplizierten GERD als Alternative und bei unzureichendem PPI-Effekt auf die Symptome auch als Erg\u00e4nzung zu einem PPI (add-on) in Betracht. Bei persistierenden Refluxbeschwerden sowie einer nicht heilenden Reflux\u00f6sophagitis ist eine differenzierte endoskopische und funktionsanalytische Diagnostik zur Ursachenkl\u00e4rung erforderlich. Extra\u00f6sophageale Manifestationen der\n\t\t\t\t\tGERD, wie z.\u200aB. Husten, R\u00e4usperzwang, Stimmprobleme und Globusgef\u00fchl, sprechen h\u00e4ufig nicht auf eine Antirefluxtherapie an. Neue Daten sprechen daf\u00fcr, dass es sich um komplexe Hypersensitivit\u00e4tssyndrome handelt, bei denen Reflux nur einer von mehreren m\u00f6glichen Ausl\u00f6sern ist.<\/jats:p>","DOI":"10.1055\/a-1309-2368","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T01:24:03Z","timestamp":1613611443000},"page":"176-187","source":"Crossref","is-referenced-by-count":1,"title":["Die konservative Therapie der Refluxkrankheit und ihre Grenzen"],"prefix":"10.1055","volume":"146","author":[{"given":"Joachim","family":"Labenz","sequence":"additional","affiliation":[{"name":"Innere Medizin, Diakonie Klinikum, Jung-Stilling-Krankenhaus Siegen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus","volume":"101","author":"N Vakil","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11377-016-0045-0","article-title":"Pr\u00e4valenz und nat\u00fcrlicher Verlauf der gastro\u00f6sophagealen Refluxkrankheit","volume":"11","author":"J Labenz","year":"2016","journal-title":"Gastroenterologe"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","article-title":"Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review","volume":"63","author":"H B El-Serag","year":"2014","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/gutjnl-2013-306393","article-title":"Symptomatic reflux disease: the present, the past and the future","volume":"63","author":"G Boeckxstaens","year":"2014","journal-title":"Gut"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.cgh.2019.07.015","article-title":"Phenotypes of gastroesophageal reflux disease: where Rome, Lyon, and Montreal meet","volume":"18","author":"D A Katzka","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.2016.5657","article-title":"Association of acute gastroesophageal reflux disease with esophageal histologic changes","volume":"315","author":"K B Dunbar","year":"2016","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jclinepi.2003.10.010","article-title":"Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study","volume":"57","author":"M Kulig","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"ref8","first-page":"1299","article-title":"[S2\u2009k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013]","volume":"52","author":"H Koop","year":"2014","journal-title":"Z Gastroenterol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ajg.2012.466","article-title":"Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study","volume":"108","author":"E Ness-Jensen","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s10620-019-05940-9","article-title":"Ninety-six hour wireless esophageal pH study in patients with GERD shows that restrictive diet reduces esophageal acid exposure","volume":"65","author":"G Triadafilopoulos","year":"2020","journal-title":"Dig Dis Sci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1055\/s-0042-121021","article-title":"Gastro\u00f6sophageale Refluxkrankheit \u2013 was tun, wenn PPI nicht ausreichend wirksam, vertr\u00e4glich oder erw\u00fcnscht sind?","volume":"142","author":"J Labenz","year":"2017","journal-title":"Dtsch Med Wochenschr"},{"key":"ref12","first-page":"477","article-title":"The indications, applications, and risks of proton pump inhibitors \u2013 a review after 25 years","volume":"113","author":"J M\u00f6ssner","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2018.08.001","article-title":"Proton pump inhibitors: what the internist needs to know","volume":"103","author":"S J Spechler","year":"2019","journal-title":"Med Clin North Am"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/apt.13194","article-title":"Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies","volume":"41","author":"S E Attwood","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"P Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","article-title":"Proton pump inhibitors alter the composition of the gut microbiota","volume":"65","author":"M A Jackson","year":"2016","journal-title":"Gut"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.14309\/ajg.0000000000000061","article-title":"Patients\u02bc perceptions of proton pump inhibitor risks and attempts at discontinuation: a national survey","volume":"114","author":"J E Kurlander","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.14309\/ajg.0000000000000558","article-title":"Physican\u02bcs perceptions of proton pump inhibitor risks and recommendations to discontinue: a national survey","volume":"115","author":"J E Kurlander","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1053\/gast.2001.27997","article-title":"Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal","volume":"121","author":"J Fletscher","year":"2001","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MCG.0000000000000439","article-title":"The role of the acid pocket in gastroesophageal reflux disease","volume":"50","author":"D R Mitchell","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/gut.2009.178061","article-title":"The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD","volume":"59","author":"H Beaumont","year":"2010","journal-title":"Gut"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.cgh.2013.04.046","article-title":"An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease","volume":"11","author":"W O Rohof","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"G975","DOI":"10.1152\/ajpgi.00424.2014","article-title":"Topical protection of human esophageal mucosal integrity","volume":"308","author":"P Woodland","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref24","first-page":"1276","article-title":"[The acid pocket \u2013 a novel target for the treatment of gastro-esophageal reflux disease]","volume":"56","author":"M Sauer","year":"2018","journal-title":"Z Gastroenterol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/147323001003800208","article-title":"A randomized, controlled, crossover trial to investigate times to onset of the perception of soothing and cooling by over-the-counter heartburn treatments","volume":"38","author":"V Strugala","year":"2010","journal-title":"J Int Med Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/apt.12640","article-title":"Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) \u2013 a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease","volume":"39","author":"E Thomas","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dow020","article-title":"Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis","volume":"30","author":"D A Leiman","year":"2017","journal-title":"Dis Esophagus"},{"key":"ref28","first-page":"12","article-title":"Gaviscon\u00ae vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. A direct comparative randomised trial","volume":"23","author":"D Pouchain","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/apt.15611","article-title":"Review article: the management of heartburn during pregnancy and lactation","volume":"51","author":"C S Th\u00e9lin","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/apt.13458","article-title":"Review article: the current treatment of non-cardiac chest pain","volume":"43","author":"N George","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1365-2036.2010.04406.x","article-title":"Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies","volume":"32","author":"H El-Serag","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"S 04","key":"ref32","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1007\/s15006-016-8303-0","article-title":"Unzureichende Symptomkontrolle unter Langzeittherapie mit PPI bei GERD \u2013 Fakt oder Fiktion?","volume":"158","author":"J Labenz","year":"2016","journal-title":"MMW Fortschr Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2019.12.014","article-title":"Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms","volume":"158","author":"S D Delshad","year":"2020","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1811424","article-title":"Randomized trial of medical versus surgical treatment for refractory heartburn","volume":"381","author":"S J Spechler","year":"2019","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/nmo.12644","article-title":"Patients with refractory reflux symptoms: what do they have and how should they be managed?","volume":"27","author":"P J Kahrilas","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00228-008-0576-5","article-title":"Relative potency of proton-pump inhibitors \u2013 comparison of effects on intragastric pH","volume":"65","author":"J Kirchheiner","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/gutjnl-2017-314722","article-title":"Modern diagnosis of GERD: the Lyon consensus","volume":"67","author":"C P Gyawali","year":"2018","journal-title":"Gut"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/dox022","article-title":"Foregut symptoms, somatoform tendencies, and the selection of patients for antireflux surgery","volume":"30","author":"K H Fuchs","year":"2017","journal-title":"Dis Esophagus"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.gtc.2020.04.003","article-title":"Evaluation and treatment of patients with persistent reflux symptoms despite proton pump inhibitor treatment","volume":"49","author":"S J Spechler","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1053\/j.gastro.2007.09.039","article-title":"Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease","volume":"133","author":"R Schey","year":"2007","journal-title":"Gastroenterology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1442-2050.2011.01276.x","article-title":"Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial","volume":"25","author":"N Manabe","year":"2012","journal-title":"Dis Esophagus"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/apt.13567","article-title":"Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor","volume":"43","author":"C Reimer","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref43","first-page":"e30","article-title":"[Alginate on demand as add-on for patients with gastro-oesophageal reflux disease and insufficient PPI effect]","volume":"144","author":"M M\u00fcller","year":"2019","journal-title":"Dtsch Med Wochenschr"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cgh.2014.06.025","article-title":"Effects of antidepressants in patients with functional esophageal disorders or gastroesophageal reflux disease: a systematic review","volume":"13","author":"P W Weijenborg","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref45","first-page":"40","article-title":"[Gastroesophageal reflux disease beyond PPI]","volume":"160","author":"J Labenz","year":"2018","journal-title":"MMW Fortschr Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/apt.12933","article-title":"Editorial: healing of refractory reflux oesophagitis\u2013an ongoing unmet clinical need","volume":"40","author":"R H Hunt","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.cgh.2018.02.001","article-title":"Extraesophageal symptoms and diseases attributed to GERD: where is the pendulum swinging now?","volume":"16","author":"M F Vaezi","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pupt.2008.12.014","article-title":"TRPV1 receptors in sensitisation of cough and pain reflexes","volume":"22","author":"J J Adcock","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"issue":"S 01","key":"ref49","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1007\/s00408-009-9185-z","article-title":"The cough hypersensitivity syndrome: a novel paradigm for understanding cough","volume":"188","author":"A H Morice","year":"2010","journal-title":"Lung"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/2050640613513016","article-title":"Pharyngeal pH alone is not reliable for the detection of pharyngeal reflux events: A study with oesophageal and pharyngeal pH-impedance monitoring","volume":"1","author":"M Desjardin","year":"2014","journal-title":"United European Gastroenterol J"}],"container-title":["Zentralblatt f\u00fcr Chirurgie - Zeitschrift f\u00fcr Allgemeine, Viszeral-, Thorax- und Gef\u00e4\u00dfchirurgie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1309-2368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:56:42Z","timestamp":1618361802000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1309-2368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":50,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2021,4,13]]},"published-print":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1309-2368","relation":{},"ISSN":["0044-409X","1438-9592"],"issn-type":[{"value":"0044-409X","type":"print"},{"value":"1438-9592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]}}}